Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer

LIESA DZIGGEL, MARKUS DAHLKE, STEFAN JANSSEN, DAGMAR HORNUNG, OLIVER BLANCK, MAI TRONG KHOA, STEVEN E. SCHILD and DIRK RADES
Anticancer Research December 2015, 35 (12) 6793-6797;
LIESA DZIGGEL
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARKUS DAHLKE
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFAN JANSSEN
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
2Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAGMAR HORNUNG
3Department of Radiation Oncology, University Medical Center Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OLIVER BLANCK
4CyberKnife Centre Northern Germany, Güstrow, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAI TRONG KHOA
5Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEVEN E. SCHILD
6Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIRK RADES
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rades.dirk@gmx.net
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To generate a tool that estimates the probability of developing new cerebral metastases after stereotactic radiosurgery (SRS) in breast cancer patients. Patients and Methods: SRS dose plus seven characteristics (age, performance score, number of cerebral metastases, maximum diameter of all metastases, location of metastases, extra-cerebral spread and time from breast cancer diagnosis until SRS) were analyzed regarding their ability to predict the probability of new cerebral metastases development following SRS. For those characteristics deemed significant, points of 0 (higher risk of new lesions) or 1 (lower risk) were given. Scores were generated by adding the points of significant characteristics. Results: Performance score (p=0.013) and maximum diameter of all metastases (p=0.022) were associated with development of subsequent brain metastases. Two groups were created, 0-1 and 2 points. Freedom from new cerebral metastases rates were 27% and 92%, respectively, at 15 months (p=0.003). Conclusion: This tool helps select breast cancer with few cerebral metastases receiving SRS who may benefit from additional whole-brain irradiation.

  • Cerebral metastases
  • breast cancer
  • stereotactic radiosurgery
  • freedom from new cerebral metastases
  • prognostic tool

Out of all patients with cerebral metastases, those with breast cancer account for 20-25% and, therefore, require for special attention (1, 2). A considerable number of these patients present with few brain lesions and are treated with stereotactic radiosurgery (SRS). Among physicians involved in the treatment of cerebral metastases, controversy exists whether some could benefit from adding whole-brain irradiation (WBI) to SRS.

Several studies have shown that the combined approach (SRS plus WBI) results in both improved local control of irradiated lesions and improved freedom from new cerebral metastases outside the irradiated areas of the brain compared to SRS-alone (3-6). This is a strong argument to add WBI to treatment schedule. On the other hand, addition of WBI does not translate into survival benefit. Furthermore, two randomized trials demonstrated that SRS plus WBI resulted in a significant increase in neuro-cognitive deficits (7, 8). However, those two trials investigated neuro-cognitive function at only 3 and 4 months, respectively, following radiotherapy. At one year, when intra-cerebral control was significantly better after SRS-plus-WBI than after SRS-alone, neuro-cognitive function was not assessed in either trial. Since several studies have shown that an intra-cerebral recurrence (and not WBI) is the most important reason for a decline in neuro-cognitive function, both randomized trials may be of limited value in judging the role of WBI in addition to SRS (9, 10) for patients living beyond 4 months. Therefore, it is still unclear whether SRS-plus-WBI or SRS-alone is the better option for few brain metastases in the long-term.

Patients who are at high risk of developing new cerebral metastases outside the irradiated areas after SRS alone are those most likely to benefit from the addition of WBI. In order to identify these patients prior to start of treatment, a predictive tool would be helpful. Such tools have already been developed in a cohort of patients treated with SRS alone for few cerebral metastases from several different primary tumor types and from malignant melanoma (11, 12). Since specific tumor types vary considerably with respect to prognosis and patterns of spread, it has been recognized that specific tools for single tumor types such as breast cancer are required to deliver optimal individualized care. Therefore, the present study aimed to provide a tool specifically for breast cancer patients with few cerebral lesions that allows for prediction of probability of developing new cerebral metastases following SRS alone.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Characteristics evaluated with respect to new brain metastases following SRS.

Patients and Methods

In this retrospective study, 34 patients receiving SRS alone for few (1 to 3) cerebral lesions from breast cancer were included. The SRS doses were 18-20 Gy prescribed to the margin of the metastatic lesions (75-85% isodose). The SRS dose (18-19 Gy vs. 20 Gy) plus seven other characteristics were evaluated for potential associations with freedom from new brain metastases following SRS. These seven characteristics were as follows: age (≤58 years vs. ≥59 years; median=58 years), Karnofsky performance score (70-80 vs. 90-100; median=90), number of cerebral metastases (n=1 vs. n=2-3), maximum diameter of all metastases (representing the sum of the maximum diameters of all lesions; ≤15mm vs. >15mm), location of metastases (supra-tentorial alone vs. infra-tentorial involvement), extra-cerebral spread (no vs. yes), and time from diagnosis of breast cancer until SRS (≤48 months vs. ≥49 months, median=48.5 months). Characteristics are summarized in Table I.

For analysis with respect to freedom from new cerebral metastases, a Kaplan-Meier analysis plus log-rank-test were used. The characteristics that showed a significant (p<0.05) association with subsequent cerebral metastases risk were included in the prognostic tool. For each of the significant characteristics, points of 0 (higher risk of developing new lesions) or 1 (lower risk of developing new lesions) were given. For each patient, the prognostic score was calculated by adding the points of each of these significant characteristics.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Analysis with respect to freedom from new cerebral metastases.

Results

Two of the investigated characteristics had a significant impact on freedom from new cerebral metastases, Karnofsky performance score (p=0.013) and the maximum diameter of all cerebral lesions (p=0.022). The findings from the analyses of freedom from new cerebral metastases for each characteristic are provided in Table II.

Considering the scoring of the two significant characteristics as shown in Table III, prognostic scores of 0, 1 or 2 points were obtained. The corresponding rates of freedom from new cerebral metastases were 64%, 63% and 100%, respectively, at 6 months, and 48%, 63% and 92%, respectively, at 1 year (p=0.009). Based on these data, two groups were created, 0-1 points and 2 points. The rates of freedom from new cerebral metastases of these groups were 63% and 100%, respectively, at 6 months, 54% and 92%, respectively, at 1 year, and 27% and 92%, respectively, at 15 months (p=0.003). The Kaplan-Meier-curves of both groups are presented in Figure 1.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan-Meier-curves of the prognostic groups 0-1 points and 2 points.

Discussion

Treatment of breast cancer has further improved during the last decade, and more breast cancer patients live longer (13-19). Since the risk of developing metastases to the brain increases with life time, the number of breast cancer patients presenting with brain metastases has increased and will likely further increase in the future. The majority of these patients have several lesions when diagnosed with cerebral metastases and receive WBI alone (2, 20-22). However, a considerable proportion of patients presenting with metastases to the brain have only few lesions. Many of these patients are suitable for local therapies such as surgical resection and SRS (23-25). In patients with 1 to 3 cerebral metastases, SRS has been shown to be superior to resection with respect to local control of treated lesions (23-25). Therefore, many patients with a limited number of cerebral metastases receive SRS, either alone or combined with WBI.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Characteristics associated with freedom from new cerebral metastases and corresponding points.

The role of WBI when added to SRS is very controversial with most physicians currently leaning against its use. This is primarily based on the findings from 2 widely publicized randomized trials. In one of these two trials, the decline in neuro-cognitive function was significantly greater at four months after combined treatment than after SRS alone (96% vs. 52%) (7). However, the 1-year intra-cerebral control rates were 73% and 27%, respectively (p=0.0003). Unfortunately, the authors did not assess the neuro-cognitive functions at 1 year when the majority of patients who did not receive WBI had subsequent brain metastases elsewhere. Previous studies have shown that intra-cerebral recurrence is the major cause of neuro-cognitive decline (9, 10). Thus, the results of this trial may be less conclusive with respect to the value of adding WBI to SRS. A second randomized trial of patients with few cerebral metastases recently presented in abstract form has similar limitations (8). Neuro-cognitive function was assessed only at 3 months following treatment (SRS-plus-WBI vs. SRS-alone), and not at 6 months or 12 months when intra-cerebral control was significantly better after SRS plus WBI than after SRS alone (88% vs. 66% at 6 months, and 85% vs. 51% at 12 months, p<0.001).

Therefore, the role of additional WBI should be further studied and clarified especially for patients living more than 3 or 4 months. A prognostic tool that can estimate the probability of developing new cerebral metastases would be valuable. Patients at a higher risk of developing new lesions may benefit from the addition of WBI, whereas in patients at lower risk, WBI could be safely ommitted. In the present study such a tool was created. The ideal condition would for availability of separate tools for patients with cerebral metastases to exist for each particular type of primary tumor, taking into account the diverging biology of each tumor type. Therefore, this study focused on a single primary tumor type, breast cancer. Two characteristics, performance status and maximum diameter of all cerebral metastases, were identified as having a significant impact on the risk of new cerebral metastases following SRS alone. These two characteristics form the basis of this prognostic tool, that includes two prognostic groups (0-1 vs. 2 points). Out of patients with 2 points, only 8% had new cerebral lesions at 15 months following SRS alone and would, therefore, not potentially benefit from the addition of WBI. Out of patients with 0-1 points, 73% had new metastases at 15 months. Therefore, patients with 0-1 points could benefit from additional WBI.

In conclusion, the present study provides a new prognostic tool for the estimation of the probability of breast cancer patients with few cerebral metastases to develop new lesions within the brain after SRS alone. Therefore, this tool will be helpful when physicians consider whether WBI should be added to SRS.

Footnotes

  • Conflicts of Interest

    On behalf of all Authors, the corresponding Author states that there is no conflict of interest related to this study.

  • Received August 12, 2015.
  • Revision received September 10, 2015.
  • Accepted September 14, 2015.
  • Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Khuntia D,
    2. Brown P,
    3. Li J,
    4. Mehta MP
    : Whole-brain radiotherapy in the management of brain metastases. J Clin Oncol 24: 1295-1304, 2006.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Tsao MN,
    2. Rades D,
    3. Wirth A,
    4. Lo SS,
    5. Danielson BL,
    6. Gaspar LE,
    7. Sperduto PW,
    8. Vogelbaum MA,
    9. Radawski JD,
    10. Wang JZ,
    11. Gillin MT,
    12. Mohideen N,
    13. Hahn CA,
    14. Chang EL
    : Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2: 210-225, 2012.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rades D,
    2. Kueter JD,
    3. Hornung D,
    4. Veninga T,
    5. Hanssens P,
    6. Schild SE,
    7. Dunst J
    : Comparison of stereotactic radiosurgery (SRS) alone and whole-brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. Strahlenther Onkol 184: 655-662, 2008.
    OpenUrlCrossRefPubMed
    1. Aoyama H,
    2. Shirato H,
    3. Tago M,
    4. Nakadawa K,
    5. Toyoda T,
    6. Hatano K,
    7. Kenjyo M,
    8. Oya N,
    9. Horota S,
    10. Snioura H,
    11. Kunieda E,
    12. Inomata T,
    13. Hayakawa K,
    14. Katoh N,
    15. Kobashi G
    : Stereotactic radiosurgery plus whole-brain radiation therapy vs.stereotactic radiosurgery alone for treatment of brain metastases. A randomized controlled trial. JAMA 295: 2483-2491, 2006.
    OpenUrlCrossRefPubMed
    1. Rades D,
    2. Huttenlocher S,
    3. Hornung D,
    4. Blanck O,
    5. Schild SE,
    6. Fischer D
    : Do patients with very few brain metastases from breast cancer benefit from whole-brain radiotherapy in addition to radiosurgery? Radiat Oncol 9: 267, 2014.
    OpenUrlPubMed
  4. ↵
    1. Rades D,
    2. Huttenlocher S,
    3. Hornung D,
    4. Blanck O,
    5. Schild SE
    : Radiosurgery alone versus radiosurgery plus whole-brain irradiation for very few cerebral metastases from lung cancer. BMC Cancer 14: 931, 2014.
    OpenUrlPubMed
  5. ↵
    1. Chang EL,
    2. Wefel JS,
    3. Hess KR,
    4. Allen PK,
    5. Lang FF,
    6. Kornguth DG,
    7. Arbuckle RB,
    8. Swint JM,
    9. Shiu AS,
    10. Maor MH,
    11. Meyers CA
    : Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10: 1037-1044, 2009.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Brown PD,
    2. Asher AL,
    3. Ballman KV,
    4. Farace E,
    5. Cerhan JH,
    6. Anderson SK,
    7. Carrero XW,
    8. Barker FG,
    9. Deming RL,
    10. Burri S,
    11. Menard C,
    12. Chzng C,
    13. Stieber VW,
    14. Pollock BE,
    15. Galanis E,
    16. Buckner JC,
    17. Jaeckle KA
    : NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol 33: suppl; abstr. LBA4, 2015.
  7. ↵
    1. Meyers CA,
    2. Smith JA,
    3. Bezjak A,
    4. Mehta MP,
    5. Liebmann J,
    6. Illidge T,
    7. Kunkler I,
    8. Caudrelier JM,
    9. Eisenberg PD,
    10. Meerwaldt J,
    11. Siemers R,
    12. Carrie C,
    13. Gaspar LE,
    14. Curran W,
    15. Phan SC,
    16. Miller RA,
    17. Renschler MF
    : Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22: 157-165, 2004.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Aoyama H,
    2. Tago M,
    3. Kato N,
    4. Toyoda T,
    5. Kenjyo M,
    6. Hirota S,
    7. Shioura H,
    8. Inomata T,
    9. Kunieda E,
    10. Hayakawa K,
    11. Nakagawa K,
    12. Kobashi G,
    13. Shirato H
    : Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68: 1388-1395, 2007.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Huttenlocher S,
    2. Dziggel L,
    3. Hornung D,
    4. Blanck O,
    5. Schild SE,
    6. Rades D
    : A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone. Radiat Oncol 9: 215, 2014.
    OpenUrlPubMed
  10. ↵
    1. Huttenlocher S,
    2. Sehmisch L,
    3. Schild SE,
    4. Blank O,
    5. Hornung D,
    6. Rades D
    : Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. Anticancer Res 34: 5589-5592, 2014.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Igglezou M,
    2. Vareli K,
    3. Georgiou GK,
    4. Sainis I,
    5. Briasoulis E
    : Kinetics of circulating levels of miR-195, miR-155 and miR-21 in patients with breast cancer undergoing mastectomy. Anticancer Res 34: 7443-7447, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Bruno A,
    2. Pandolfo G,
    3. Scimeca G,
    4. Leonardi V,
    5. Cedro C,
    6. Racchiusa S,
    7. Zoccali RA,
    8. Muscatello MR
    : Anger in Health, Benign Breast Disease and Breast Cancer: A Prospective Case–Control Study. In Vivo 28: 973-977, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Yeh DC,
    2. Chen DR,
    3. Chao TY,
    4. Chen SC,
    5. Wang HC,
    6. Rau KM,
    7. Feng YH,
    8. Chang YC,
    9. Lee KD,
    10. Yang FO,
    11. Kuo WH,
    12. Chang KJ,
    13. Lin YC,
    14. Tseng LM,
    15. Hou MF
    : EORTC QLQ-BM22 Quality of Life Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with Zoledronic Acid. In Vivo 28: 1001-1004, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Lien MY,
    2. Liu LC,
    3. Wang HC,
    4. Yeh MH,
    5. Chen CJ,
    6. Yeh SP,
    7. Bai LY,
    8. Liao YM,
    9. Lin CY,
    10. Hsieh CY,
    11. Lin CC,
    12. Li LY,
    13. Lin PH,
    14. Chiu CF
    : Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. Anticancer Res 34: 7319-7326, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Hahn A,
    2. Schlotter CM,
    3. Rossmanith WG,
    4. Ulmer HU,
    5. Staiger HJ,
    6. Villena C
    : Neoadjuvant Chemotherapy for Breast Cancer with Weekly Nab-paclitaxel Followed by Epirubicin and Cyclophosphamide – Results of a Case Series. In Vivo 28: 235-241, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Kim KY,
    2. Chung BW,
    3. Yang I,
    4. Kim MB,
    5. Hoffman RM
    : Independence of cytotoxic drug sensitivity profiles and receptor subtype of invasive ductal breast carcinoma demonstrated by the histoculture drug response assay (HDRA). Anticancer Res 34: 7197-7201, 2014.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Usiakova Z,
    2. Mikulova V,
    3. Pinterova D,
    4. Brychta M,
    5. Valchar J,
    6. Kubecova M,
    7. Tesatova P,
    8. Bobek V,
    9. Kolostova K
    : Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success. In Vivo 28: 605-614, 2014.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Rades D,
    2. Dziggel L,
    3. Segedin B,
    4. Oblak I,
    5. Nagy V,
    6. Marita A,
    7. Schild SE,
    8. Trang NT,
    9. Khoa MT
    : A simple survival score for patients with brain metastases from breast cancer. Strahlenther Onkol 189: 664-667, 2013.
    OpenUrlPubMed
    1. Rades D,
    2. Dziggel L,
    3. Nagy V,
    4. Segedin B,
    5. Lohynska R,
    6. Veninga T,
    7. Khoa MT,
    8. Trang NT,
    9. Schild SE
    : A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiother Oncol 108: 123-127, 2013.
    OpenUrlPubMed
  14. ↵
    1. Dziggel L,
    2. Segedin B,
    3. Podvrsnik NH,
    4. Oblak I,
    5. Schild SE,
    6. Rades D
    : Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 189: 364-366, 2013.
    OpenUrlPubMed
  15. ↵
    1. Rades D,
    2. Kueter JD,
    3. Veninga T,
    4. Gliemroth J,
    5. Schild SE
    : Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: Results of a matched pair analysis. Eur J Cancer 45: 400-404, 2009.
    OpenUrlPubMed
    1. Rades D,
    2. Veninga T,
    3. Hornung D,
    4. Wittkugel O,
    5. Schild SE,
    6. Gliemroth J
    : Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection. Cancer 118: 1138-1144, 2012.
    OpenUrlPubMed
  16. ↵
    1. O'Neill BP,
    2. Iturria NJ,
    3. Link MJ,
    4. Pollock BE,
    5. Ballman KV,
    6. O'Fallon JR
    : A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55: 1169-1176, 2003.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 35 (12)
Anticancer Research
Vol. 35, Issue 12
December 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer
LIESA DZIGGEL, MARKUS DAHLKE, STEFAN JANSSEN, DAGMAR HORNUNG, OLIVER BLANCK, MAI TRONG KHOA, STEVEN E. SCHILD, DIRK RADES
Anticancer Research Dec 2015, 35 (12) 6793-6797;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer
LIESA DZIGGEL, MARKUS DAHLKE, STEFAN JANSSEN, DAGMAR HORNUNG, OLIVER BLANCK, MAI TRONG KHOA, STEVEN E. SCHILD, DIRK RADES
Anticancer Research Dec 2015, 35 (12) 6793-6797;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast
  • Predicting the Risk of Developing New Cerebral Lesions After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastases from Renal Cell Carcinoma
  • A Score to Identify Patients with Brain Metastases from Colorectal Cancer Who May Benefit from Whole-brain Radiotherapy in Addition to Stereotactic Radiosurgery/Radiotherapy
  • Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases
  • Rotating Gamma System Irradiation: A Promising Treatment for Low-grade Brainstem Gliomas
  • Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas
  • Outcomes After Whole-brain Radiotherapy for Brain Metastases with 5x4 Gy: Importance of Overall Treatment Time
  • Potential Impact of the Overall Treatment Time on Outcomes after Whole-brain Irradiation with 10x3 Gy for Brain Metastases
  • Google Scholar

More in this TOC Section

  • A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study
  • Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
  • Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • cerebral metastases
  • Breast cancer
  • stereotactic radiosurgery
  • freedom from new cerebral metastases
  • prognostic tool
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire